OssDsign Crescita futura
Criteri Future verificati 2/6
OssDsign prevede che gli utili e i ricavi cresceranno rispettivamente di 35.4% e 23.8% all'anno. Si prevede che l'EPS crescerà di 38.3% all'anno. Si prevede che il ritorno sul capitale proprio sarà di -12.7% in 3 anni.
Informazioni chiave
35.4%
Tasso di crescita degli utili
38.33%
Tasso di crescita dell'EPS
| Medical Equipment crescita degli utili | 22.0% |
| Tasso di crescita dei ricavi | 23.8% |
| Rendimento futuro del capitale proprio | -12.69% |
| Copertura analitica | Low |
| Ultimo aggiornamento | 06 May 2026 |
Aggiornamenti recenti sulla crescita futura
Recent updates
Aggiornamento della narrazione • Jun 04
OSSD: Refined Forecast Assumptions Will Support Future Upside Potential
Analysts have maintained their SEK fair value estimate for OssDsign while updating inputs such as revenue growth, profit margin, discount rate and a lower future P/E assumption. Together, these changes support a refined price target framework without altering the headline SEK figure.Aggiornamento della narrazione • May 03
OSSD: Higher Long Term Margins And Moderate P/E Will Support Future Upside
Analysts have revised their price target for OssDsign to SEK 5.1 from SEK 13.5. The change reflects updated assumptions around growth, profitability and a more moderate future P/E multiple. What's in the News OssDsign issued earnings guidance for the first quarter of 2026, indicating a loss before interest and taxes in the range of SEK 12.0 million to SEK 14.0 million, with only marginal exchange rate impact (Key Developments).
Aggiornamento della narrazione • Apr 18
OSSD: Stable Loss Outlook And Assumptions Will Support Future Multiple Re Rating
Analysts have kept their OssDsign price target steady at SEK 12.75, indicating only marginal tweaks in the discount rate, long term revenue growth, profit margin and future P/E assumptions, rather than any major shift in their view of the company. What's in the News OssDsign issued earnings guidance for the first quarter of 2026, focusing on loss before interest and taxes rather than revenue or profit metrics.Aggiornamento della narrazione • Apr 04
OSSD: Stable Profitability Assumptions Will Support Future Multiple Re rating
Analysts keep their SEK 12.75 price target on OssDsign unchanged, citing steady assumptions around growth, margins, and a future P/E near 113x as the basis for maintaining the current valuation. Valuation Changes Fair Value: SEK 12.75 remains unchanged, so the target valuation level is consistent with prior assumptions.Aggiornamento della narrazione • Mar 20
OSSD: Stable Assumptions Will Support Long Term Margin Expansion
Analysts have maintained their SEK 12.75 price target for OssDsign, citing stable assumptions on fair value, discount rate, revenue growth, profit margin and future P/E as the basis for this unchanged view. Valuation Changes Fair Value: SEK 12.75 remains unchanged, signalling a stable central valuation estimate.Aggiornamento della narrazione • Mar 05
OSSD: New US Leadership Will Support Long Term Margin Expansion
Analysts have kept their OssDsign price target steady at SEK 12.75, citing largely unchanged assumptions around fair value, discount rate, revenue growth, profit margin, and future P/E as the basis for maintaining their view. What's in the News OssDsign AB appointed Mark Waugh as CEO, effective January 1, 2026, following his senior roles at Smith & Nephew plc, Medtronic Sofamor Danek Inc, and Medacta USA (Key Developments).Aggiornamento della narrazione • Feb 19
OSSD: New US-Focused Leadership Will Support Long Term Margin Expansion
Analysts are maintaining their SEK 12.75 price target on OssDsign. They point to a slightly higher discount rate, broadly similar revenue growth assumptions at around 26%, a lower profit margin outlook, and a higher future P/E expectation as key inputs behind this unchanged view.Aggiornamento della narrazione • Feb 04
OSSD: US Leadership Change Will Support Long Term Margin Expansion
Analysts have reduced their price target on OssDsign to €12.75 from €15.50, citing updated assumptions for growth, margins, and a lower future P/E multiple. What's in the News OssDsign AB appointed Mark Waugh as CEO, with his tenure set to begin on January 1, 2026, following a leadership transition from current CEO Morten Henneveld (Key Developments).Aggiornamento della narrazione • Jan 20
OSSD: New US Based Leadership Will Drive Future Orthobiologics Expansion
Analysts have kept their price target for OssDsign steady at €13.50, citing only marginal adjustments to the discount rate, revenue growth, profit margin and forward P/E assumptions that together are not enough to shift their overall valuation view. What's in the News OssDsign AB appointed Mark Waugh as CEO, effective January 1, 2026, following his senior roles at Smith & Nephew, Medtronic Sofamor Danek, and Medacta USA (company announcement).Aggiornamento della narrazione • Jan 06
OSSD: New US Focused Leadership Will Shape Bullish Future Outlook
Analysts have adjusted their price target on OssDsign to $13.50, reflecting updated assumptions around revenue growth, profit margin and a much higher implied future P/E multiple, while keeping their fair value estimate unchanged at $13.50. What's in the News OssDsign AB appointed Mark Waugh as CEO, effective January 1, 2026, following five years of leadership under outgoing CEO Morten Henneveld (Key Developments).Aggiornamento della narrazione • Dec 13
OSSD: New Leadership And Index Inclusion Will Shape Balanced Future Outlook
The analyst price target for OssDsign has been raised from SEK 12.0 to SEK 13.5, as analysts factor in a higher long term valuation multiple despite slightly slower projected revenue growth and a softer profit margin profile. What's in the News OssDsign AB appointed Mark Waugh as CEO, effective January 1, 2026, succeeding Morten Henneveld after five years of leading the company through growth and transformation (company announcement) New CEO Mark Waugh brings over 20 years of international leadership experience across major orthopedic segments in the USA and Europe, including senior roles at Smith & Nephew, Medtronic Sofamor Danek, and Medacta USA (company announcement) OssDsign Catalyst driven orthobiologics focus has supported strong double digit growth in the U.S. market since its launch in August 2021 (company announcement) OssDsign AB (publ) has been added to the S&P Global BMI Index, increasing its visibility to international institutional investors (index provider) Valuation Changes Fair Value: Raised from SEK 12.0 to SEK 13.5, reflecting a modest upward revision in the company’s long term valuation.Aggiornamento della narrazione • Aug 08
Pure Play Orthobiologics Will Expand US Healthcare Access
With OssDsign's consensus price target revised lower, primarily driven by a notable drop in its Future P/E from 77.22x to 64.47x, the fair value estimate has decreased from SEK15.67 to SEK14.83. What's in the News An undisclosed buyer acquired an unknown minority stake in OssDsign AB from Karolinska Development AB.Articolo di analisi • May 08
Optimistic Investors Push OssDsign AB (publ) (STO:OSSD) Shares Up 31% But Growth Is Lacking
OssDsign AB (publ) ( STO:OSSD ) shareholders would be excited to see that the share price has had a great month...
Nuova narrazione • Apr 07
Pure Play Orthobiologics Will Expand US Healthcare Access
Strategic shift to orthobiologics boosts growth and operational efficiency, enhancing future revenue and sustaining high net margins.Articolo di analisi • Feb 21
OssDsign AB (publ)'s (STO:OSSD) 25% Price Boost Is Out Of Tune With Revenues
OssDsign AB (publ) ( STO:OSSD ) shares have continued their recent momentum with a 25% gain in the last month alone...Articolo di analisi • Feb 07
Analysts Are Upgrading OssDsign AB (publ) (STO:OSSD) After Its Latest Results
OssDsign AB (publ) ( STO:OSSD ) defied analyst predictions to release its full-year results, which were ahead of market...Articolo di analisi • Nov 15
OssDsign AB (publ) (STO:OSSD) Just Reported Earnings, And Analysts Cut Their Target Price
OssDsign AB (publ) ( STO:OSSD ) just released its latest quarterly results and things are looking bullish. OssDsign...Articolo di analisi • Nov 13
OssDsign AB (publ)'s (STO:OSSD) Share Price Matching Investor Opinion
OssDsign AB (publ)'s ( STO:OSSD ) price-to-sales (or "P/S") ratio of 5.7x might make it look like a sell right now...Articolo di analisi • Aug 23
OssDsign AB (publ) (STO:OSSD) Just Reported Earnings, And Analysts Cut Their Target Price
Last week, you might have seen that OssDsign AB (publ) ( STO:OSSD ) released its quarterly result to the market. The...Articolo di analisi • Aug 06
We Think OssDsign (STO:OSSD) Can Afford To Drive Business Growth
Just because a business does not make any money, does not mean that the stock will go down. For example, although...Articolo di analisi • Jun 19
Increases to OssDsign AB (publ)'s (STO:OSSD) CEO Compensation Might Cool off for now
Key Insights OssDsign's Annual General Meeting to take place on 25th of June CEO Morten Henneveld's total compensation...Articolo di analisi • Mar 19
Getting In Cheap On OssDsign AB (publ) (STO:OSSD) Is Unlikely
OssDsign AB (publ)'s ( STO:OSSD ) price-to-sales (or "P/S") ratio of 8.5x might make it look like a strong sell right...Previsioni di crescita degli utili e dei ricavi
| Data | Ricavi | Utili | Flusso di cassa libero | Liquidità dell'operazione | Avg. Numero di analisti |
|---|---|---|---|---|---|
| 12/31/2028 | 308 | -14 | -37 | -27 | 3 |
| 12/31/2027 | 238 | -36 | -47 | -42 | 3 |
| 12/31/2026 | 168 | -51 | -66 | -49 | 3 |
| 3/31/2026 | 173 | -48 | -65 | -53 | N/A |
| 12/31/2025 | 180 | -51 | -71 | -64 | N/A |
| 9/30/2025 | 176 | -42 | -59 | -54 | N/A |
| 6/30/2025 | 168 | -46 | -57 | -53 | N/A |
| 3/31/2025 | 151 | -53 | -62 | -60 | N/A |
| 12/31/2024 | 134 | -50 | -63 | -62 | N/A |
| 9/30/2024 | 127 | -90 | -81 | -81 | N/A |
| 6/30/2024 | 123 | -114 | -91 | -91 | N/A |
| 3/31/2024 | 118 | -118 | -95 | -95 | N/A |
| 12/31/2023 | 112 | -130 | -94 | -94 | N/A |
| 9/30/2023 | 97 | -109 | -93 | -93 | N/A |
| 6/30/2023 | 83 | -95 | -93 | -93 | N/A |
| 3/31/2023 | 71 | -99 | -92 | -92 | N/A |
| 12/31/2022 | 57 | -99 | -86 | -86 | N/A |
| 9/30/2022 | 46 | -96 | -82 | -82 | N/A |
| 6/30/2022 | 38 | -93 | -98 | -98 | N/A |
| 3/31/2022 | 33 | -95 | -90 | -90 | N/A |
| 12/31/2021 | 32 | -94 | -90 | -90 | N/A |
| 9/30/2021 | 29 | -90 | -94 | -93 | N/A |
| 6/30/2021 | 27 | -92 | -77 | -76 | N/A |
| 3/31/2021 | 23 | -90 | -83 | -80 | N/A |
| 12/31/2020 | 25 | -85 | -82 | -79 | N/A |
| 9/30/2020 | 24 | -89 | -81 | -79 | N/A |
| 6/30/2020 | 22 | -89 | -90 | -88 | N/A |
| 3/31/2020 | 22 | -85 | -87 | -86 | N/A |
| 12/31/2019 | 18 | -84 | N/A | -87 | N/A |
| 9/30/2019 | 18 | -72 | N/A | -90 | N/A |
| 6/30/2019 | 20 | -66 | N/A | -75 | N/A |
| 3/31/2019 | 21 | -62 | N/A | -78 | N/A |
| 12/31/2018 | 21 | -56 | N/A | -66 | N/A |
| 12/31/2017 | 16 | -63 | N/A | -41 | N/A |
Previsioni di crescita futura degli analisti
Guadagni vs tasso di risparmio: Si prevede che OSSD rimarrà non redditizia nei prossimi 3 anni.
Guadagni vs Mercato: Si prevede che OSSD rimarrà non redditizia nei prossimi 3 anni.
Guadagni ad alta crescita: Si prevede che OSSD rimarrà non redditizia nei prossimi 3 anni.
Ricavi vs Mercato: Si prevede che il fatturato di OSSD ( 23.8% all'anno) crescerà più rapidamente del mercato Swedish ( 0.02% all'anno).
Ricavi ad alta crescita: Si prevede che il fatturato di OSSD ( 23.8% all'anno) crescerà più rapidamente di 20% all'anno.
Previsioni di crescita dell'utile per azione
Rendimento futuro del capitale proprio
ROE futuro: Si prevede che OSSD non sarà più redditizia tra 3 anni.
Scoprire le aziende in crescita
Analisi aziendale e situazione dei dati finanziari
| Dati | Ultimo aggiornamento (ora UTC) |
|---|---|
| Analisi dell'azienda | 2026/06/15 10:24 |
| Prezzo dell'azione a fine giornata | 2026/06/15 00:00 |
| Utili | 2026/03/31 |
| Utili annuali | 2025/12/31 |
Fonti dei dati
I dati utilizzati nella nostra analisi aziendale provengono da S&P Global Market Intelligence LLC. I seguenti dati sono utilizzati nel nostro modello di analisi per generare questo report. I dati sono normalizzati, il che può comportare un ritardo nella disponibilità della fonte.
| Pacchetto | Dati | Tempistica | Esempio Fonte USA * |
|---|---|---|---|
| Dati finanziari della società | 10 anni |
| |
| Stime di consenso degli analisti | +3 anni |
|
|
| Prezzi di mercato | 30 anni |
| |
| Proprietà | 10 anni |
| |
| Gestione | 10 anni |
| |
| Sviluppi principali | 10 anni |
|
* Esempio per i titoli statunitensi, per i titoli non statunitensi si utilizzano forme e fonti normative equivalenti.
Se non specificato, tutti i dati finanziari si basano su un periodo annuale ma vengono aggiornati trimestralmente. Si tratta dei cosiddetti dati TTM (Trailing Twelve Month) o LTM (Last Twelve Month). Per saperne di più.
Modello di analisi e Snowflake
I dettagli del modello di analisi utilizzato per generare questo report sono disponibili sulla nostra pagina Github; abbiamo anche guide su come utilizzare i nostri report e tutorial su Youtube.
Scoprite il team di livello mondiale che ha progettato e realizzato il modello di analisi Simply Wall St.
Metriche di settore e industriali
Le nostre metriche di settore e di sezione sono calcolate ogni 6 ore da Simply Wall St; i dettagli del nostro processo sono disponibili su Github.
Fonti analitiche
OssDsign AB (publ) è coperta da 3 analisti. 3 di questi analisti ha fornito le stime di fatturato o di utile utilizzate come input per il nostro report. Le stime degli analisti vengono aggiornate nel corso della giornata.
| Analista | Istituzione |
|---|---|
| null null | ABG Sundal Collier |
| null null | ABG Sundal Collier Sponsored |
| Kristofer Liljeberg-Svensson | DNB Carnegie Commissioned Research |